TY - JOUR
T1 - ACR Appropriateness Criteria® Staging of Renal Cell Carcinoma
T2 - 2022 Update
AU - Expert Panel on Urological Imaging
AU - Ganeshan, Dhakshinamoorthy
AU - Khatri, Gaurav
AU - Ali, Norman
AU - Avery, Ryan
AU - Caserta, Melanie P.
AU - Chang, Silvia D.
AU - De Leon, Alberto Diaz
AU - Gupta, Rajan T.
AU - Lyshchik, Andrej
AU - Michalski, Jeff
AU - Nicola, Refky
AU - Pierorazio, Phillip M.
AU - Purysko, Andrei S.
AU - Smith, Andrew D.
AU - Taffel, Myles T.
AU - Nikolaidis, Paul
N1 - Funding Information:
Dr. Gupta reports Leadership roles as Chair, ACR Annual Meeting. Dr. Khatri reports Leadership roles as Division Chief, Body MRI, Interim Division Chief, Abdominal Imaging, University of Texas Southwestern Medical Center, Dallas. Dr. Lyshchik reports Grants or contracts from Research support: GE Healthcare, Bracco Diagnostics, Canon Medical; Royalties or licenses from Elsevier; Consulting fees from GE Healthcare, Bracco Diagnostics; Payments or honoraria from GE Healthcare, Bracco Diagnostics; Participation on an advisory board for GE Healthcare, Bracco Diagnostics; Leadership roles as ICUS Board Member. Dr. Nicola reports Royalties or licenses from Elseiver. Dr. Pierorazio reports Royalties or licenses from Up To Date article on management of small renal masses, Consulting fees from BMS one time scientific ad board regarding perioperative systemtic therapy for kidney cancer. Dr. Purysko reports Grants or contracts from Blue Earth Diagnostics, American College of Radiology; Consulting fees from Koleis Blue Earth Diagnostics; Support for meetings from Profound Medical. Dr. Smith reports Royalties or licenses from AI Metrics and Body Check; Patents from Multiple utility patents; Stock in AI Metrics and Body Check. Dr. Chang and Dr. Nicola are partners; and the other authors are non-partner/non-partnership track/employees.
Publisher Copyright:
© 2023 American College of Radiology
PY - 2023/5
Y1 - 2023/5
N2 - Renal cell carcinoma is a complex group of highly heterogenous renal tumors demonstrating variable biological behavior. Pretreatment imaging of renal cell carcinoma involves accurate assessment of the primary tumor, presence of nodal, and distant metastases. CT and MRI are the key imaging modalities used in the staging of renal cell carcinoma. Important imaging features that impact treatment include tumor extension into renal sinus and perinephric fat, involvement of pelvicalyceal system, infiltration into adrenal gland, involvement of renal vein and inferior vena cava, as well as the presence of metastatic adenopathy and distant metastases. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE are adapted to evaluate the evidence. The RAND/UCLA Appropriateness Method User Manual provides the methodology to determine the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where peer reviewed literature is lacking or equivocal, experts may be the primary evidentiary source available to formulate a recommendation.
AB - Renal cell carcinoma is a complex group of highly heterogenous renal tumors demonstrating variable biological behavior. Pretreatment imaging of renal cell carcinoma involves accurate assessment of the primary tumor, presence of nodal, and distant metastases. CT and MRI are the key imaging modalities used in the staging of renal cell carcinoma. Important imaging features that impact treatment include tumor extension into renal sinus and perinephric fat, involvement of pelvicalyceal system, infiltration into adrenal gland, involvement of renal vein and inferior vena cava, as well as the presence of metastatic adenopathy and distant metastases. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE are adapted to evaluate the evidence. The RAND/UCLA Appropriateness Method User Manual provides the methodology to determine the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where peer reviewed literature is lacking or equivocal, experts may be the primary evidentiary source available to formulate a recommendation.
KW - AUC
KW - Appropriate Use Criteria
KW - Appropriateness Criteria
KW - CT
KW - MRI
KW - Nephrectomy
KW - Renal cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85160377691&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85160377691&partnerID=8YFLogxK
U2 - 10.1016/j.jacr.2023.02.008
DO - 10.1016/j.jacr.2023.02.008
M3 - Article
C2 - 37236747
AN - SCOPUS:85160377691
SN - 1546-1440
VL - 20
SP - S246-S264
JO - Journal of the American College of Radiology
JF - Journal of the American College of Radiology
IS - 5
ER -